Category-defining therapy — Settled science — No incumbent — $15B by 2030 —Category-defining therapy — Settled science — No incumbent — $15B by 2030 —Category-defining therapy — Settled science — No incumbent — $15B by 2030 —Category-defining therapy — Settled science — No incumbent — $15B by 2030 —Category-defining therapy — Settled science — No incumbent — $15B by 2030 —Category-defining therapy — Settled science — No incumbent — $15B by 2030 —Category-defining therapy — Settled science — No incumbent — $15B by 2030 —Category-defining therapy — Settled science — No incumbent — $15B by 2030 —Category-defining therapy — Settled science — No incumbent — $15B by 2030 —Category-defining therapy — Settled science — No incumbent — $15B by 2030 —Category-defining therapy — Settled science — No incumbent — $15B by 2030 —Category-defining therapy — Settled science — No incumbent — $15B by 2030 —Category-defining therapy — Settled science — No incumbent — $15B by 2030 —Category-defining therapy — Settled science — No incumbent — $15B by 2030 —Category-defining therapy — Settled science — No incumbent — $15B by 2030 —Category-defining therapy — Settled science — No incumbent — $15B by 2030 —
Investors

A first-in-class therapy in a market with no incumbent.

A $15B addressable opportunity by 2032. No approved implantable competitor. Built on clinical science that is already settled. Stimalia is creating the category.

Why now01 — 02
01

The science risk is gone

Stellate ganglion modulation produces meaningful PTSD response in 70–80% of treated patients across multiple peer-reviewed studies. The mechanism works. The bet is on execution, not biology.

02

The market is empty

Injection-based blocks are transient, inconsistent, and unscalable. No durable, implantable, programmable solution exists. The category is open and Stimalia is first to it.

03

The regulatory wind is favorable

FDA Breakthrough Device pathways and EU MDR designations now exist for severe unmet psychiatric needs. Government and military payers are increasingly active in PTSD reimbursement.

The opportunity02 — 02
~$15B
Addressable PTSD market by 2032
24M
Adults affected EU + US
70–80%
Response rate published SGB studies
0
Approved implantable competitors

“A category-defining therapy. A market with no incumbent.”

Request investor materials →

Stimalia

Bioelectronic medicine · Louvain La Neuve · est. 2025